Q-omics provides the consensus-scored RND3 profile across patient tissues and cancer cell-line models. RND3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RND3 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, RND3 RNA expression shows 17,982 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, KIRP, and THYM as cancer lineages where RND3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RND3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RND3 survival associations across molecular data types. RND3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RND3 RNA expression–survival associations across cancer types. High RND3 expression shows unfavorable associations in MESO, KIRP, LUAD, OV and LGG, but favorable associations in UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for RND3 RNA expression.
This table summarizes RND3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRP for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RND3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RND3 shows lower tumor expression in LIHC, BRCA, BLCA and KICH and higher tumor expression in KIRP and KIRC. The KIRP box plot shows higher RND3 RNA expression in tumor versus normal tissue (log2 FC = +1.950, t-test p < 0.001).
This table shows molecular features associated with RND3 in patient tissues and cancer cell lines. In patient samples, RND3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, RND3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
